1995
Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease
Price L, Spencer D, Marek K, Robbins R, Leranth C, Farhi A, Naftolin F, Roth R, Bunney B, Hoffer P, Makuch R, Redmond D. Psychiatric status after human fetal mesencephalic tissue transplantation in Parkinson's disease. Biological Psychiatry 1995, 38: 498-505. PMID: 8562661, DOI: 10.1016/0006-3223(95)00129-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBrain Tissue TransplantationCaudate NucleusDepressive DisorderDopamineFemaleFetal Tissue TransplantationFollow-Up StudiesHumansMaleMesencephalonMiddle AgedNeurocognitive DisordersNeuropsychological TestsPanic DisorderParkinson DiseasePostoperative ComplicationsProspective StudiesConceptsParkinson's diseasePsychiatric statusHuman fetal mesencephalic tissueAdrenal medullary graftsAdrenal medullary transplantationFetal mesencephalic tissueSystematic psychiatric assessmentPerioperative sequelaeMesencephalic tissuePsychiatric sequelaeCaudate nucleusPsychiatric assessmentNeurobiological effectsBehavioral symptomsTissue transplantationDiseasePatientsTransplantationSequelaeSuch episodesEpisodesGroup effectsStatusDeliriumDiscrete episodesGeneral Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease
Sass K, Buchanan C, Westerveld M, Marek K, Farhi A, Robbins R, Naftolin F, Vollmer T, Leranth C, Roth R, Price L, Bunney B, Elsworth J, Hoffer P, Redmond D, Spencer D. General Cognitive Ability Following Unilateral and Bilateral Fetal Ventral Mesencephalic Tissue Transplantation for Treatment of Parkinson's Disease. JAMA Neurology 1995, 52: 680-686. PMID: 7619024, DOI: 10.1001/archneur.1995.00540310050016.Peer-Reviewed Original ResearchConceptsCognitive abilitiesNonverbal cognitive abilityVerbal cognitive abilityInformation-processing speedVerbal memoryNeuropsychological profileTest batteryCognitive functionNormal cognitive functionCognitive dysfunctionRight caudate nucleusCaudate nucleusFactor analysisTissue transplantationParkinson's disease
1993
In vivo assessment of basal and drug‐induced dopamine release in cortical and subcortical regions of the anesthetized primate
Moghaddam B, Berridge C, Goldman‐Rakic P, Bunney B, Roth R. In vivo assessment of basal and drug‐induced dopamine release in cortical and subcortical regions of the anesthetized primate. Synapse 1993, 13: 215-222. PMID: 8497807, DOI: 10.1002/syn.890130304.Peer-Reviewed Original ResearchConceptsExtracellular dopamine levelsBasal extracellular dopamine levelsDopamine levelsPrefrontal cortexPremotor cortexDrug-induced dopamine releaseVivo assessmentExtracellular concentrationNonhuman primatesBasal extracellular concentrationsCaudate-putamen areaFeasibility of microdialysisCortex of primatesMedial prefrontal cortexDorsolateral prefrontal cortexCortical dopamineIntracerebral microdialysisIntravenous administrationNeurological illnessDopamine releaseSubcortical areasCortical areasDopamine projectionsDopamine systemSubcortical regionsCellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients.
Redmond D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B. Cellular replacement of dopamine deficit in Parkinson's disease using human fetal mesencephalic tissue: preliminary results in four patients. Proceedings Of The Association For Research In Nervous And Mental Disease 1993, 71: 325-59. PMID: 8417471.Peer-Reviewed Original Research
1992
Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease
Spencer D, Robbins R, Naftolin F, Marek K, Vollmer T, Leranth C, Roth R, Price L, Gjedde A, Bunney B, Sass K, Elsworth J, Kier E, Makuch R, Hoffer P, Redmond D. Unilateral Transplantation of Human Fetal Mesencephalic Tissue into the Caudate Nucleus of Patients with Parkinson's Disease. New England Journal Of Medicine 1992, 327: 1541-1548. PMID: 1435880, DOI: 10.1056/nejm199211263272201.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAdultAntiparkinson AgentsCaudate NucleusCryopreservationCyclosporineDopamineFemaleFetal Tissue TransplantationHomovanillic AcidHumansMagnetic Resonance ImagingMaleMesencephalonMiddle AgedMotor ActivityParkinson DiseasePutamenStereotaxic TechniquesTomography, Emission-ComputedConceptsCase patientsParkinson's diseaseMesencephalic tissueCaudate nucleusHuman fetal ventral mesencephalic tissueFetal ventral mesencephalic tissueHuman fetal mesencephalic tissueContinued disease progressionFetal dopaminergic neuronsFetal mesencephalic tissueVentral mesencephalic tissueSevere Parkinson's diseaseOptimal drug therapySigns of parkinsonismMidbrain dopamine neuronsPositron emission tomographyMonths of evaluationAntiparkinsonian medicationUnilateral transplantationDrug holidayMore medicationsStriatonigral degenerationNeurologic functionDopaminergic neuronsDrug therapyClozapine: A Hypothesised Mechanism for its Unique Clinical Profile
Bunney B. Clozapine: A Hypothesised Mechanism for its Unique Clinical Profile. The British Journal Of Psychiatry. Supplement 1992, 160: 17-21. PMID: 1418885, DOI: 10.1192/s0007125000296864.Peer-Reviewed Original Research
1986
Does the cholecystokinin antagonist proglumide possess antipsychotic activity?
Innis R, Bunney B, Charney D, Price L, Glazer W, Sternberg D, Rubin A, Heninger G. Does the cholecystokinin antagonist proglumide possess antipsychotic activity? Psychiatry Research 1986, 18: 1-7. PMID: 3737785, DOI: 10.1016/0165-1781(86)90056-9.Peer-Reviewed Original ResearchConceptsPsychosis ratingsPlacebo-controlled studyRole of cholecystokininCentral dopaminergic activityCCK receptor antagonistsPathogenesis of schizophreniaMesocortical neuronsNeuroleptic medicationNeurotransmitter statusReceptor antagonistDopaminergic activityAntipsychotic activitySchizophrenic patientsCholecystokininNegative findingsPreclinical researchProglumidePatientsSchizophreniaPotential reasonsMedicationsPathogenesisAntagonistMidbrainNeuropeptides
1985
The treatment of tardive dyskinesia with baclofen
Glazer W, Moore D, Bowers M, Bunney B, Roffman M. The treatment of tardive dyskinesia with baclofen. Psychopharmacology 1985, 87: 480-483. PMID: 3936106, DOI: 10.1007/bf00432517.Peer-Reviewed Original Research